15/05/2014 - 17:45
Treatment with empagliflozin, an investigational sodium-glucose cotransporter 2 (SGLT2) inhibitor, was associated with benefits for blood pressure as well as glycemic control in a 3-month study of...
Field of Interest: Endocrinology
Categories:
News Feed: Internal Medicine News - Endocrinology